Danicopan Completed Phase 2 Trials for C3 Glomerulonephritis / Complement 3 Glomerulopathy (C3G) / Membranoproliferative Glomerulonephritis Types I, II, and III / Membranoproliferative Glomerulonephritis, Type II / Immune Complex Mediated Membranoproliferative Glomerulonephritis Basic Science

Indications	Status	Purpose	Phase
DBCOND0062399 (C3 Glomerulonephritis) DBCOND0138498 (Complement 3 Glomerulopathy (C3G)) DBCOND0140871 (Membranoproliferative Glomerulonephritis Types I, II, and III) DBCOND0088371 (Membranoproliferative Glomerulonephritis, Type II) DBCOND0088373 (Immune Complex Mediated Membranoproliferative Glomerulonephritis)	Completed	Basic Science	2

clinicaltrials.gov Identifier	Title	Drugs
NCT03124368	A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN	Danicopan (DB15401)